Navigation Links
VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
Date:5/23/2011

rpharma is also well advanced in its planning of studies to determine the efficacy of VivaGel(R) for this second BV indication and expects to commence this trial in Q3 2011. The very high early cure rate observed in this study is an important observation that is highly relevant to and supportive of the application of VivaGel(R) for prevention of BV recurrence.

About Bacterial Vaginosis
BV is the most common vaginal infection worldwide and is particularly prevalent in the US, where it affects an estimated one-third of the adult female population. Similar to imbalances between "good" and "bad" bacteria in the gut, an imbalance in the vaginal microbiota between good bacteria - which help maintain a normal healthy vagina - and harmful bacteria, leads to BV with symptoms including vaginal irritation, discharge and odour that are unpleasant and disrupt and interfere with a woman's relationships and general quality of life. The condition also has more serious consequences, being implicated in pelvic inflammatory disease and associated with an increased risk of pre-term birth. BV also significantly increases the risk of some sexually transmitted infections, including HIV.

Several studies have found an association between BV and acquisition of HIV, with one study indicating that more than 30% of HIV infections in women could be prevented if BV was successfully treated. Therefore, treatment of BV with VivaGel(R) could have a positive indirect impact in reducing HIV acquisition.

Other Applications of VivaGel(R)
VivaGel(R) is also being developed as a topical microbicide for the prevention of HIV and genital herpes and as a condom coating. Prevention of human papillomavirus is also under assessment.  

For a copy of the clinical appendix please go to http://www.starpharma.com/news-room

For Further Information:
Media:
Buchan Consulting
Rebecca Wilson
Mob: +61-417-3
'/>"/>

SOURCE Starpharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Feb. 1, 2011 /PRNewswire-Asia-FirstCall/ --  China Medicine Corporation ... "Company"), a leading manufacturer, developer and distributor of ... health products in the People,s Republic of China, ... manufacturing license from the Chinese Ministry of Agriculture ...
... 2011 Stryker Corporation (NYSE: SYK ) ... of its OP-1 product family, which includes OP-1 Implant, ... bone applications. The transaction also includes the sale of ... Stryker is one of the world,s leading medical technology ...
Cached Medicine Technology:China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... at night, which shuts off nighttime production of the ... a widely used breast cancer drug, says a new ... The study, "Circadian and Melatonin Disruption by Exposure to ... in Breast Cancer," published in the journal Cancer ... is vital to the success of tamoxifen in treating ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay News) ... wrong, according to a small study that asked boys what they ... between the ages of 14 and 16, researchers found that most ... and trust. Very few boasted about sexual conquests or saw sex ... "In our culture, we have lots of assumptions about how ...
(Date:7/24/2014)... Pools and beaches are the place to ... dangerous, especially for small children, so Amica Insurance ... to the Centers for Disease Control and Prevention, children between ... for water-related injuries and deaths. It’s important to know the ... Amica is offering the following tips from the American Red ...
Breaking Medicine News(10 mins):Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... on Science, Not IdeologyWASHINGTON, March 23 Today, the ... York ruled that the Food and Drug Administration (FDA) ... dedicated emergency contraceptive product) based on age was "arbitrary ... faith decision-making." The court ordered the FDA to extend ...
... Recommended levels in foods need to be increased, experts ... the course of two decades, vitamin D levels have ... Low levels of vitamin D have been associated with ... adults. Recent research has also linked insufficient vitamin D ...
... seen with tightest control of risk factors, researchers report ... control of the major risk factors for heart disease ... a new study shows. , And so the current ... LDL cholesterol might need to be tightened even further, ...
... a Decision Based on Scientific Fact, Not PoliticsNEW YORK, March ... the Eastern District of New York rejected the Food and ... emergency contraceptive Plan B to women over 18, ruling that ... The court ordered the agency to reconsider its decision. ...
... in Virginia, West Virginia and Maryland to hold annual convention recognizing ... ... 23, 2009 -- 200 emergency and 911 professionals will gather in ... safety sector. The 16th Annual Tri-State Telecommunicators Banquet and Awards ...
... Inform Healthcare DecisionsPHILADELPHIA, March 23 ... when selecting a hospital for treatment, thanks to ... and facility.Synthesizing extensive data from the 2003-2007 ... Hospital Performance Reports (PHC4) into a searchable format, ...
Cached Medicine News:Health News:Advocates for Youth Applauds Court Ruling on EC Age Restriction 2Health News:Many Americans Fall Short on Their Vitamin D 2Health News:Many Americans Fall Short on Their Vitamin D 3Health News:Many Americans Fall Short on Their Vitamin D 4Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 2Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 3Health News:LLE to Sponsor 16th Annual Tri-State Telecommunicators Banquet and Awards Ceremony 2Health News:New Site Compares Pennsylvania Hospitals 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: